David Lillicrap

Genetic basis of familial Meniere's disease.

Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.

Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.

Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy.

A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.

The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.

A survey of recommendations by gynecologists in Canada regarding oral contraceptive use in the perioperative period.

Gene expression: overview and clinical implications.

Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease.

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.

Preclinical animal models for hemophilia gene therapy: predictive value and limitations.

A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G>A) causes skipping of 2 nonadjacent exons.

Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.

Reliability and reproducibility of classification of children as "bleeders" versus "non-bleeders" using a questionnaire for significant mucocutaneous bleeding.

Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.

Cell type-specific regulation of von Willebrand factor expression by the E4BP4 transcriptional repressor.

Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease.

Aminoglycoside suppression of nonsense mutations in severe hemophilia.

Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.

Genetic testing for von Willebrand disease: the Canadian experience.

The role of immunomodulation in the management of factor VIII inhibitors.

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study.

Correction of the bleeding time in von Willebrand factor (VWF)-deficient mice using murine VWF.

Theories of blood coagulation.

Von Willebrand: the scientist, the disease, the factor, and the treatment.

Von Willebrand disease - phenotype versus genotype: deficiency versus disease.

Distinguishing between non-identical twins: platelet type and type 2B von Willebrand disease.

Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

Von Willebrand disease.

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response.

Coagulation factors--molecular attributes and their clinical impact.

Extending half-life in coagulation factors: where do we stand?

ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.

The role of molecular genetics in diagnosing von Willebrand disease.

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.

[Application studies on the gene diagnosis and carrier detection of hemophilia A by using polymerase chain reaction-conformation sensitive gel electrophoresis].

Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.

Characterization of viability and proliferation of alginate-poly-L-lysine-alginate encapsulated myoblasts using flow cytometry.

Improvements in factor concentrates.

Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.

Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B.

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.

Challenges and innovations in the treatment of bleeding disorders.

Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.

Early intraoperative blood collection does not affect complete blood counts, von Willebrand factor or factor VIII levels in normal children.

A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.

Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study.

Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models.

Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease.

The diagnosis and management of von Willebrand disease in Canada.

Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

von Willebrand disease: Clinical and laboratory lessons learned from the large von Willebrand disease studies.

The World Federation of Hemophilia and research.

A complex substitute: antibody therapy for hemophilia.

The future of hemostasis management.

Alloantibodies in von Willebrand disease.

The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.

Introduction to a series of reviews on cancer-associated thrombotic disease.

The Canadian "National Program for hemophilia mutation testing" database: a ten-year review.

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Genetic sequence analysis of inherited bleeding diseases.

von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.

Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.

FVIII stabilization: VWF D'D3 will do.

Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation.

Syntaxin-binding protein 5 exocytosis regulation: differential role in endothelial cells and platelets.

Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Introduction to a series of reviews on inherited bleeding disorders.

Journal of Thrombosis and Haemostasis. Special Issue: State of the Art 2015. Preface.

To clear or to fear: An innate perspective on factor VIII immunity.

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII.

War and peace: Factor VIII and the adaptive immune response.

Foreword.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.

Gene Therapy for Coagulation Disorders.

How much do we really know about von Willebrand disease?

Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Summary report of the First International Conference on inhibitors in haemophilia A.

Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A.

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.

Bispecific Antibody Therapy in Hemophilia.